KWM
ENTA icon

Kingsview Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Kingsview Wealth Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,653
Closed -$168K – 1363
2025
Q4 		$168K Buy
+10,653
New +$135K ﹤0.01% 1190

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Kingsview Wealth Management's ENTA Position: Q1 2026 in Review

Kingsview Wealth Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 10,653 shares — an estimated $168K sold.

Kingsview Wealth Management first reported a position in ENTA in Q4 2025 and held it in 1 quarter. The position peaked at $168K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Kingsview Wealth Management reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Kingsview Wealth Management sold 10,653 Enanta Pharmaceuticals shares in Q1 2026, an estimated $168K.
  • Kingsview Wealth Management first reported a position in Enanta Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Kingsview Wealth Management's Enanta Pharmaceuticals position peaked at $168K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.